Parkinson Disease

Phase 1 trial of gene therapy for Parkinson disease presented at AANS meeting

Published in Gene Therapy Weekly, May 26th, 2005

Neurologix Inc. (NRGX) announced that on April 20, 2005, its scientific co-founder, Michael G. Kaplitt, MD, PhD, presented a clinical update as the company sponsored landmark phase 1 gene therapy trial for the treatment of Parkinson disease nears completion.

This update was given at the 73rd annual meeting of the American Association of Neurological Surgeons (AANS) held in New Orleans, Louisiana.

Kaplitt highlighted the rationale for targeting the overactive subthalamic nucleus in Parkinson disease patients with the GAD (glutamic acid decarboxylase) gene, which synthesizes the major inhibitory neurotransmitter in the brain, gamma-aminobutyric acid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry